SMMT News

Latest breaking news and updates for SMMT stock.

Track all markets on TradingView

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi trial featuring the novel, potentia...

What is the expected impact of the HARMONi trial results on Summit’s valuation multiples relative to peers? Will the data release affect the company’s upcoming earnings guidance or financial outlook? How does the anticipated market size for ivonescimab’s target indication compare to competitors’ pipelines?
Clinical trials
10 days ago
Read more businesswire

SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Aug. 12, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Summit Therapeutics Inc. ("Summit"...

What is the likelihood of the lawsuit expanding to include additional claims or parties beyond the current class action? Could the outcome of the case trigger a material change in Summit's governance or executive leadership? How does this lawsuit compare to other ongoing legal challenges within the biotech sector?
Lawsuits
12 days ago
Read more prnewswire

SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $SMMT--SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm

How should position sizing and risk management be adjusted in response to the increased volatility risk? What impact might this have on the broader sector or related competitor stocks? Could this lawsuit trigger additional regulatory scrutiny for Summit Therapeutics and its industry peers?
Lawsuits
12 days ago
Read more businesswire

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for t...

What are the potential upside and downside scenarios for the stock based on ivonescimab’s clinical trial outcomes? How will the operational progress update affect analyst coverage and earnings forecasts for the remainder of 2025? Is there any indication of upcoming data readouts or conference presentations that could move the price?
Earnings
13 days ago
Read more businesswire